Looking forward to sharing our research on tumor heterogeneity tomorrow morning @WinshipAtEmory Grand Rounds and spending some time with the @EmoryRadOncRes residents!

Still time to register! Join our esteemmed faculty ⁦@EmoryUniversity ⁦@WinshipAtEmory⁩ Updates in #HNCA https://t.co/3LZShVVcGk on September 6th; ⁦@StokedStokes⁩ ⁦@NikkiSchmittMD⁩ ⁦@ConorSteuerMD⁩

Georgia Democrats, as our next Chair, I’ll have one job: Elect as many Democrats as possible. I’m honored to launch my bid for Chair with the support of so many community leaders and party activists from all corners of our state: https://t.co/5VcVxKErWh

Please join us on April 26th, 2025 for our Radiotherapy Frontiers Educational Workshop. We will go over all of the latest advances in radiotherapy, including LDRT for Arthritis and other benign indications.

We are thrilled to announce that EA3211 now includes *metachronous* oligometastatic disease, provided the primary site has been disease-free for at least 6 months. Please consider opening up this study to answer this important question in metastatic HNSCC!

Countdown to #ASTRO24 - We'll be highlighting some oral and poster must-see abstracts from RTOG and NRG research in the coming month as we get ready for this year's ASTRO Annual Meeting. Full NRG & RTOG Research Schedule: https://t.co/IL3fPFGpE5

New on the ASTROblog: Head and Neck Cancer Patients may have their Dental Services Covered by Medicare. Read it here: https://t.co/K4DwIIAiRJ

Congrats to Winship medical physicist and researcher Richard Castillo, PhD, who has been elected a Fellow of the American Association of Physicists in Medicine (@aapmHQ). ➡️Read more: https://t.co/Wg6ucPMk43

Congrats @ebludmir and @ChadTangMD! This @MDAndersonNews P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer

Viewpoint discusses the importance of hormone deprivation–free survival as an end point for both men with prostate cancer and women with breast cancer.

IMHO all types of systemic therapy-free survival are more clinically meaningful endpoints than objective response rates et similia

New Post! Thank you to Dr. Michael Baddour, Head & Neck Surgeon at Emory University, who composed this expert review of the importance of understanding perineural spread in cutaneous squamous cell carcinomas of the head and neck. #AHNSSkin @AHNSinfo https://t.co/gGorb2A8NY

WOW! HPV ctDNA detection at 3 months after dCRT for anal canal cancer associated with 100% risk of recurrence! 8% with HPV ctDNA negative #ASCO24

🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine +/- erlotinib (no benefit with erlotinib) 🔥2nd Randomization🔥 +/- Chemoradiation, 50.4 Gy/28 fx + cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #asco24

We're so busy that we have opened another HN rad onc position @MoffittNews. If interested in joining at team of 4 HN rad oncs, including me, Dr. M Echevarria, @BeekeepRadOnc, and soon @RadOncDoc_Niema, send me your CV.

Excited to share Varian’s Study Guide for #RadOnc residents for the Physics Boards Exam! Register at the QR code for access to videos, quizzes, practice tests, and more 📚. And the best part.. it’s free! Thank you Varian!

Denver should be fun! H&N day is Friday. Bring your skin protection and See you there! #hncsm

📣41 amazing #RadOnc #MedEd abstracts submitted for #ROECSG24. We look forward to hearing about all the great work going on around the globe on Friday 5/31/24. Still haven't registered? It's free! Go to https://t.co/ihd6vZkP8S for details. In-person and virtual options.

As a physician, championing for my patients, following NCCN guidelines, I get a rejection from OSCAR insurance company for ISRT (Involved Site Radiotherapy) for lymphoma. When I ask for peer to peer, the only time they have available is at 8:30 PM!.. wow. IS THIS FAIR ?

Shameful. @BCBSkc denies PSMA PET for high risk prostate cancer. P2P with IM physician who is unable to approve because doesn’t meet Carelon (BCBS) guidelines. I’m pretty sure Carelon’s outdated guidelines are killing pts by delaying care across the US for aggressive cancer.